Rosamicin--a new drug for the treatment of bacterial prostatitis.
Rosamicin, a new macrolide substance, was investigated in dogs and humans with regard to its usefulness for the treatment of bacterial prostatitis and compared with the well-known macrolide erythromycin. In dogs with normal and experimentally infected prostates, concentration ratios for rosamicin in prostatic secretion, interstitial fluid (obtained from implanted tissue chambers), and tissue were significantly higher than for erythromycin. The difference was even more pronounced in human prostatic tissue, obtained by transurethral resection. With its broad spectrum against many common urinary pathogens, rosamicin seems to be a promising drug for the treatment of acute and chronic bacterial prostatitis.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D004285:Dogs; D004917:Erythromycin / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use; D004927:Escherichia coli Infections / Q000188:drug therapy; D006801:Humans; D008297:Male; D011467:Prostate / Q000378:metabolism; D011472:Prostatitis / Q000188:drug therapy* / Q000209:etiology
D000900:Anti-Bacterial Agents; D004917:Erythromycin